Synageva BioPharma Inactive 10-Q2011 Q3 Quarterly report

Filed: 14 Nov 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abandon, Abbey, acquiror, adult, Agent, aggressively, alter, altogether, apparent, art, asserted, assessment, ASU, attain, automatically, award, bear, begun, behalf, BESP, billing, body, breach, breached, bring, Britain, broader, burden, capped, Carsten, case, children, circumvented, claim, claimed, commensurate, commit, contractor, conventional, Cosmetic, criteria, crucial, curtail, debt, Deficiency, degree, deliverable, deny, deprive, desirable, desired, developmental, diagnosed, disagree, disappointing, disease, document, documentation, duly, dysfunction, ease, educate, educated, efficacy, EITF, element, eligibility, eligible, enable, encumber, enroll, enrolling, entirety, entity, Europe, eventually, exemplified, Exhibit, exhibiting, expand, experimental, exploit, exposed, expression, expressly, external, extrapolated, February, fill, fixed, focused, forfeiture, forgo, formatted, formulate, Foundation, fraction, fractional, France, freedom, fulfill, fundraising, GAAP, Georgia, Germany, GEVA, goodwill, greatly, guarantee, guidance, heavily, Heberlig, HTML, iii, imply, inability, inadequate, inconclusive, incorrect, Index, industry, inherent, inside, insist, inspection, instance, institute, institutional, intangible, intercompany, interfere, invalid, invalidated, invoice, invoiced, Italy, iv, Julian, Label, labeled, labeling, labor, laboratory, LAL, Language, larger, Ledgemont, length, lesser, licensor, lieu, likelihood, Linkbase, Lipase, liver, locate, low, Lysosomal, Martin, Mattingly, medicinal, methodology, Minnesota, model, modestly, modified, modify, monitored, multinational, narrowed, narrower, national, nature, noncompliance, onset, opposition, orphan, outlined, owe, Oxford, Pangenix, par, pediatric, permanent, persuasive, Phase, pipeline, point, portrayal, preclinical, prepaid, prepayment, preserve, President, prevalence, priority, procuring, profile, promising, proportionally, prospective, purify, rapid, rapidly, rare, recordkeeping, redesign, Regulation, relinquish, removed, rendered, Rental, repeating, request, residual, restructured, resubmit, retire, safe, safety, sampling, satisfaction, Schema, science, secret, security, shorten, Silicon, site, small, sooner, sought, Spain, specialty, sponsoring, stage, staggered, standard, store, strength, strict, study, subset, substantive, sued, suspend, symbol, Synagava, tangible, target, targeted, task, Taxonomy, Tesla, therapeutic, thereunder, thereunto, threatened, TOE, tolerability, TPE, Trademark, transition, trial, twelve, UK, unacceptable, unamended, unannounced, unanticipated, uncertain, undelivered, underlying, undersigned, understanding, undesirable, uneven, unique, University, unmet, unplanned, unrelated, upheld, Valley, vendor, volume, VSOE, warrant, wholly, XBRL

Removed: accessible, blended, committee, enforcing, identical, indirectly, letter, processing, role, thereon, Unadjusted, unobservable, unrestricted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Synageva BioPharma similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Synageva BioPharma Corp. (the “Company”) for the quarterly period ended September 30, 2011 as filed with Securities and Exchange Commission on the date hereof (the “Report”), I, Sanj K. Patel, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Sanj K. Patel

Sanj K. Patel

President and Chief Executive Officer

November 14, 2011

The foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the Report or as a separate disclosure document.

A signed original of this written statement required by § 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.